EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)

被引：4

作者：

Wiland, Piotr ^{[1
]}

Jeka, Slawomir ^{[2
]}

Dokoupilova, Eva ^{[3
,4
]}

Miranda Limon, Juan Manuel ^{[5
]}

Jauch-Lembach, Julia ^{[6
]}

Thakur, Anjali ^{[6
]}

Haliduola, Halimuniyazi ^{[6
]}

Gaylis, Norman ^{[7
]}

机构：

[1] Wroclaw Med Univ, Wroclaw, Poland

[2] Coll Med UMK, 2nd Univ Hosp, Bydgoszcz, Poland

[3] MED PLUS Sro, Uherske Hradiste, Czech Republic

[4] Univ Vet & Pharmaceut Sci, Fac Pharm, Brno, Czech Republic

[5] RM Pharma Specialists, Mexico City, DF, Mexico

[6] Hexal AG, Holzkirchen, Germany

[7] Arthrit & Rheumat Dis Specialties, Aventura, FL USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2019-eular.960

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0087

引用

页码：706 / 707

页数：2